Reduce Warning Letter Threshold In Draft CPG, HIMA Advises FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA inspectors should not consider the failure of a manufacturer to meet a single inspectional objective or part of an inspectional objective as a major deficiency worthy of a warning letter, the Health Industry Manufacturers Association recommends in comments on FDA's draft compliance program guidance.